摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-烯丙基甘氨酸 | 54594-06-8

中文名称
D-烯丙基甘氨酸
中文别名
2-烯丙基-D-甘氨酸;(R)-2-氨基-4-戊烯酸;D-C-烯丙基氨基乙酸;D-2-氨基-4-戊烯酸;D-ALPHA-烯丙基甘氨酸;D-α-烯丙基甘氨酸;D-Alpha-烯丙基甘氨酸;D-烯丙基氨基乙酸
英文名称
D-allylglycine
英文别名
(R)-2-aminopent-4-enoic acid;(R)-allylglycine;(2R)-2-aminopent-4-enoic acid;(R)-2-amino-4-pentenoic acid
D-烯丙基甘氨酸化学式
CAS
54594-06-8
化学式
C5H9NO2
mdl
MFCD00063104
分子量
115.132
InChiKey
WNNNWFKQCKFSDK-SCSAIBSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    239.3-241.2 °C
  • 比旋光度:
    37 º (c=2% in H2O)
  • 沸点:
    231.0±33.0 °C(Predicted)
  • 密度:
    1.098±0.06 g/cm3(Predicted)
  • 溶解度:
    可微溶于水

计算性质

  • 辛醇/水分配系数(LogP):
    -1.6
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    67.8
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S22,S24/25,S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2922499990
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    2~8℃

SDS

SDS:b3bc61894ad89f23e3997bd10a4de8f9
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : D-Allylglycine
CAS-No. : 54594-06-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : D-2-Amino-4-pentenoic acid
(R)-(+)-2-Amino-4-pentenoic acid
Formula : C5H9NO2
Molecular Weight : 115,13 g/mol

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: crystalline
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

H-D-Gly(烯丙基)-OH是甘氨酸(HY-Y0966)的衍生物。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    针对细菌核糖体的沸腾糖苷抗生素的合理设计。
    摘要:
    天然氨基糖苷类抗生素对RNA的识别取决于2-deoxystreptamine(2-DOS)支架,该支架与核糖体解码位点的靶标形成特定的氢键。三维结构信息已用于设计氮杂单糖苷,这是新型抗生素的组成部分,其中2-DOS被杂环支架取代。阿斯庚烷-糖苷在低微摩尔范围内显示出靶标结合和翻译抑制作用,并抑制了金黄色葡萄球菌的生长,包括对氨基糖苷类耐药的菌株。
    DOI:
    10.1016/j.bmcl.2003.11.028
  • 作为产物:
    描述:
    (2R,RS)-2-(tert-butylsulfinamido)pent-4-enoic acid盐酸 作用下, 以 为溶剂, 反应 4.0h, 以69%的产率得到D-烯丙基甘氨酸
    参考文献:
    名称:
    Diastereoselective amidoallylation of glyoxylic acid with chiral tert-butanesulfinamide and allylboronic acid pinacol esters: efficient synthesis of optically active γ,δ-unsaturated α-amino acids
    摘要:
    A convenient synthesis of delta,gamma-unsaturated amino acids has been developed. After a mixture of (R)-tert-butanesulfinamide and glyoxylic acid with molecular sieves in CH2Cl2 was stirred for 42 h at room temperature, allylboronic acid pinacol ester was added to the mixture to give (R)-2-((R)-tert-butanesulfinamido)pent-4-enoic acid with high diastereoselectivity. The corresponding reaction of (Z)-crotylboronic acid pinacol ester produced no product; however, that of (E)-crotylboronic acid pinacol ester produced (2R,3S)-2-((R)-tert-butylsulfinamido)-3-methylpent-4-enoic acid with excellent diastereoselectivity. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetasy.2013.07.026
点击查看最新优质反应信息

文献信息

  • Synthesis of skeletally diverse alkaloid-like molecules: exploitation of metathesis substrates assembled from triplets of building blocks
    作者:Sushil K Maurya、Mark Dow、Stuart Warriner、Adam Nelson
    DOI:10.3762/bjoc.9.88
    日期:——
    A range of metathesis substrates was assembled from triplets of unsaturated building blocks. The approach involved the iterative attachment of a propagating and a terminating building block to a fluorous-tagged initiating building block. Metathesis cascade chemistry was used to "reprogram" the molecular scaffolds. Remarkably, in one case, a cyclopropanation reaction competed with the expected metathesis
    一系列复分解底物由三联体不饱和结构单元组装而成。该方法涉及将传播和终止构建块迭代连接到带有氟标记的起始构建块。复分解级联化学用于“重新编程”分子支架。值得注意的是,在一种情况下,环丙烷化反应与预期的复分解级联过程竞争。最后,证明复分解产物可以衍生以产生最终产物。在每个阶段,通过氟标记保护基团的存在促进纯化。
  • Highly Practical Methodology for the Synthesis of <scp>d</scp>- and <scp>l</scp>-α-Amino Acids, <i>N</i>-Protected α-Amino Acids, and <i>N</i>-Methyl-α-amino Acids
    作者:Andrew G. Myers、James L. Gleason、Taeyoung Yoon、Daniel W. Kung
    DOI:10.1021/ja9624073
    日期:1997.1.1
    step the asymmetric alkylation of pseudoephedrine glycinamide (1) or pseudoephedrine sarcosinamide (2). Practical procedures for the synthesis of 1 and 2 from pseudoephedrine and glycine methyl ester or sarcosine methyl ester, respectively, are presented. Optimum protocols for the enolization and subsequent alkylation of 1 and 2 are described. Alkylation reactions of 1 and 2 are found to be quite efficient
    提供了一种非常实用的合成 d-和 l-α-氨基酸、N-保护的 α-氨基酸和 N-甲基-α-氨基酸的方法的完整细节,其中使用伪麻黄碱甘氨酰胺的不对称烷基化作为关键步骤(1) 或伪麻黄碱肌酰胺 (2)。介绍了分别从伪麻黄碱和甘氨酸甲酯或肌氨酸甲酯合成 1 和 2 的实用程序。描述了 1 和 2 的烯醇化和随后的烷基化的最佳方案。发现 1 和 2 的烷基化反应对于范围广泛的卤代烷底物非常有效,并且产物以高非对映选择性形成。通过在水或水-二恶烷混合物中加热,这些烷基化反应的产物可以有效地水解并且几乎没有外消旋化。该协议为制备高对映体纯度的无盐 α-氨基酸提供了一种非常实用的方法。或者,烷基化产物...
  • Asymmetric [2,3]-Rearrangement of Glycine-Derived Allyl Ammonium Ylids
    作者:James A. Workman、Neil P. Garrido、Julien Sançon、Edward Roberts、Hans Peter Wessel、J. B. Sweeney
    DOI:10.1021/ja043768i
    日期:2005.2.1
    enantioselective [2,3]-sigmatropic rearrangements of acyclic allylic ammonium ylids are reported. Thus, a range of N-2'-[(N'-allyl-N',N'-dialkyl)ammonium]}acetyl camphor sultams undergo rearrangement at 0 degrees C in DME solution with high diastereofacial control (up to 99:1 dr) to give allylglycines in generally high yield. The power of the method has been demonstrated in a rapid and efficient synthesis of (R)-allyl
    报告了无环烯丙基铵叶立德的高度对映选择性 [2,3]-σ 重排的第一个例子。因此,一系列 N-2'-[(N'-烯丙基-N',N'-二烷基)铵]}乙酰樟脑 sultams 在 DME 溶液中在 0 摄氏度进行重排,具有高非对映控制(高达 99: 1 dr) 以通常高产率得到烯丙基甘氨酸。该方法的强大功能已在 (R)-烯丙基甘氨酸的快速有效合成中得到证明。
  • [EN] NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] NOUVEAUX MACROCYCLES EN TANT QU'INHIBITEURS DU FACTEUR XIA
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013022818A1
    公开(公告)日:2013-02-14
    The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    本发明提供了化合物的公式(Ia):或其立体异构体、互变异构体或药用可接受盐,其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽原的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
  • The discovery of allyltyrosine based tripeptides as selective inhibitors of the HIV-1 integrase strand-transfer reaction
    作者:Neal Dalton、Christopher P. Gordon、Timothy P. Boyle、Nicholas Vandegraaf、John Deadman、David I. Rhodes、Jonathan A. Coates、Stephen G. Pyne、Paul A. Keller、John B. Bremner
    DOI:10.1039/c6ob00950f
    日期:——
    amino acids. Resulting SAR analysis revealed the allyltyrosine residue was a key feature for IN inhibitory activity whilst incorporation of a lysine residue and extended hydrophilic chains bearing a terminal methyl ester was advantageous. Addition of hydrophobic aromatic moieties to the N-terminal of the scaffold afforded compounds with improved inhibitory activity. Consolidation of these functionalities
    从合成抗菌肽的文库筛选中,鉴定出一种基于O-烯丙基酪氨酸的三肽具有抗HIV-1整合酶(IN)的抑制活性,并具有IC 50在3'-处理和链转移微量滴定板分析的组合中的最大值为17.5μM。该三肽用28种肽进行了结构-活性关系(SAR)研究,其中包含了一系列天然和非天然氨基酸。SAR分析表明,烯丙基酪氨酸残基是IN抑制活性的关键特征,而掺入赖氨酸残基和带有末端甲酯的延长亲水链则是有利的。将疏水性芳族部分添加至支架的N-末端,提供了具有改善的抑制活性的化合物。这些功能的整合导致三肽96的发展,该三肽96特异性地抑制了IN链转移反应,其IC 50值为2.5μM。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物